Izokibep
Sponsors
Acelyrin Inc., ACELYRIN Inc.
Conditions
Hidradenitis SuppurativaIntermediate-Non-infectiousPosterior- or Pan-uveitisPsoriatic ArthritisUveitis
Phase 2
A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis
CompletedNCT04706741
Start: 2022-01-06End: 2022-11-14Updated: 2024-02-12
Hidradenitis Suppurativa Phase 2b Study of Izokibep
CompletedNCT05355805
Start: 2022-05-05End: 2024-02-21Updated: 2025-06-03
Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis
TerminatedNCT05384249
Start: 2022-08-23End: 2025-02-07Updated: 2025-02-21
Psoriatic Arthritis Study of Izokibep
TerminatedNCT05623345
Start: 2022-11-21End: 2024-08-08Updated: 2025-05-23
22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis
CompletedCTIS2022-501362-22-00
Start: 2023-04-18End: 2024-10-03Target: 78Updated: 2024-10-16
A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis
CompletedCTIS2024-514975-16-00
Start: 2022-12-22End: 2025-01-07Target: 21Updated: 2025-02-19
Phase 3
Hidradenitis Suppurativa Study of Izokibep
TerminatedNCT05905783
Start: 2023-06-22End: 2025-01-27Updated: 2025-10-15
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa
CompletedCTIS2022-503160-33-00
Start: 2023-12-15End: 2025-01-27Target: 68Updated: 2024-12-04